Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
19.47
+0.07 (0.36%)
Nov 28, 2025, 1:00 PM EST - Market closed
Denali Therapeutics Employees
Denali Therapeutics had 422 employees as of December 31, 2024. The number of employees decreased by 23 or -5.17% compared to the previous year.
Employees
422
Change (1Y)
-23
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$1,181,858
Market Cap
2.86B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 422 | -23 | -5.17% |
| Dec 31, 2023 | 445 | 18 | 4.22% |
| Dec 31, 2022 | 427 | 47 | 12.37% |
| Dec 31, 2021 | 380 | 89 | 30.58% |
| Dec 31, 2020 | 291 | 30 | 11.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DNLI News
- 7 days ago - Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 22 days ago - Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 6 weeks ago - FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate - Benzinga
- 6 weeks ago - Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) - GlobeNewsWire
- 2 months ago - Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - The Best Small-Cap Stocks to Buy Now - Kiplinger
- 3 months ago - Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 5 months ago - Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) - GlobeNewsWire